Franklin Rising Dividends Fund Q4 2025 Commentary [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
Over the quarter, Franklin Rising Dividends Fund underperformed its benchmark, the S&P 500 Index, due to stock selection, especially in the IT sector. The largest detractor was enterprise cloud software provider Oracle as rising investor concern over the scale and execution risk of its expansion weighed on sentiment. Pharmaceutical firm Eli Lilly and Co. was the top contributor as accelerating weight-loss drugs sales helped the company deliver better-than-expected quarterly revenue and earnings. We remain encouraged by dividend trends for our portfolio companies, which have continued to grow their dividends faster than the overall market. AlexSecret/E+ via Getty Images Key Takeaways • Markets: US equities delivered solid gains over the fourth quarter of 2025, maintaining their upward trajectory against a backdrop of generally robust corporate earnings, despite mixed economic signals and investor concerns about stretched technology valuations. Continued monetary This art
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US [Yahoo! Finance]Yahoo! Finance
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPR Newswire
- Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's CEO Says This Could Be a Game Changer for Its Business [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) had its price target lowered by Guggenheim from $1,168.00 to $1,163.00. They now have a "buy" rating on the stock.MarketBeat
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website